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Ankylosing spondylitis
Ankylosing spondylitis (AS) belongs to a common group 
of arthritides called spondyloarthopathies (SpA). AS 
targets primarily the spine and pelvis and is characterized 
histopathologically by entheseal infl am mation. Disease 
progression in AS is characterized by excessive bone 
formation (ankylosis) that gradually bridges the gap 
between joints, eventually fusing joints and causing stiff -
ness, pain, signifi cant morbidity, and increased mortality 
[1].
Th e coexistence of AS and intestinal infl ammation has 
been known for some time [2]. Between 5% and 10% of 
patients with AS develop clinically diagnosed infl amma-
tory bowel disease (IBD), and a further 70% of patients 
with AS develop subclinical gut infl ammation [1,2]. In 
reactive arthritis, a member of the SpA family, infl am-
matory arthritis develops following urogenital infection 
with Chlamydia trachomatis or gastrointestinal infection 
with Campylobacter, Salmonella, Shigella, or Yersinia [3]. 
Such cause-and-eff ect relationships are not established 
for other SpAs.
Genetic overlap between ankylosing spondylitis 
and gut disease
Strong genetic overlap exists between AS and IBD, and 
the two conditions commonly occur together in families 
[4]. Danoy and colleagues [5] (2010) studied genes known 
to be associated with IBD in a large AS cohort. New loci 
and genes were identifi ed, and of particular note were 
genes involved in the interleukin-23 (IL-23) pathway, 
such as STAT3, IL-23 receptor (IL23R), and IL12B (which 
encodes IL-12p40, the share subunit of IL-23 and IL-12) 
[5-7]. How these genetic lesions infl uence gut homeo-
stasis and function remains unclear. Major diff er ences 
also exist between the genetics of IBD and AS, and AS 
has shown no association to date with NOD2/CARD15 or 
the autophagy gene ATG16L1, which are major suscep-
tibility factors in IBD, whereas IBD shows no association 
with HLA-B or ERAP1, which are the strongest AS 
susceptibility genes [8]. Although no asso ciation has been 
shown with NOD2/CARD15 and AS specifi cally, poly-
morphisms in NOD2/CARD15 have been associated with 
an increased risk of gut disease in patients with SpA [9].
The gut, barrier regulation, and intestinal 
epithelial cells
Homeostasis of the normal microbial fl ora in the gut is 
essential for intestinal health. Th e gastrointestinal tract is 
heavily populated with microbes and is the primary site 
for interaction between these microorganisms and the 
immune system [10,11]. Furthermore, microbes found in 
the gut help to shape host immune systems from an early 
age. Th e incomplete development of the immune system 
in neonates and under germ-free (GF) conditions tells us 
that microbiota sculpt the host immune system [12,13].
Maintenance of intestinal and microbial homeostasis is 
increasingly recognized as playing a pivotal role in overall 
health [14], and dysregulation of either gut or microbial 
homeostasis may play a role in autoimmunity. Physio-
logical processes in the host that maintain gut homeo stasis 
and respond to perturbance in the gut micro environ ment 
involve both the adaptive and innate immune system and 
the barrier function of the intestines themselves.
Abstract
It is increasingly clear that the interaction between 
host and microbiome profoundly aff ects health. 
There are 10 times more bacteria in and on our 
bodies than the total of our own cells, and the human 
intestine contains approximately 100 trillion bacteria. 
Interrogation of microbial communities by using classic 
microbiology techniques off ers a very restricted view 
of these communities, allowing us to see only what 
we can grow in isolation. However, recent advances 
in sequencing technologies have greatly facilitated 
systematic and comprehensive studies of the role 
of the microbiome in human health and disease. 
Comprehensive understanding of our microbiome 
will enhance understanding of disease pathogenesis, 
which in turn may lead to rationally targeted therapy 
for a number of conditions, including autoimmunity.
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The physical barrier
Th e human gastrointestinal tract is not a complete 
barrier. It is composed of a single layer of intestinal 
epithelial cells (IECs), which form a physical barrier 
separating the intestinal lumen from the lamina propria 
(Figure 1). IECs secrete soluble factors that are crucial to 
intestinal homeostasis, such as mucins and anti-microbial 
peptides, including lysozymes, defensins, cathelicidins, 
lipocalins, and C-type lectins such as RegIIIγ [15-17]. 
Release of these molecules into luminal crypts is thought 
to prevent microbial invasion into the crypt micro-
environment as well as limit bacteria-epithelial cell 
contact [16,18]. Compared with healthy controls, Crohn’s 
disease patients with active disease have pronounced 
decreases in the human α-defensins DEFA5 and DEFA6 
in the ileum, resulting in altered mucosal function and 
overgrowth or dysregulation of commensal microbial 
fl ora [18,19]. Conversely, overexpression of anti-micro-
bials, including α-defensins, are reported in sub-clinically 
infl amed ileum of AS patients compared with Crohn’s 
disease patients and healthy controls [20]. However, it 
remains unclear whether changes in innate mucosal 
defenses lead to alterations in gut-resident microbial fl ora 
or whether early changes in the microbiome sculpt 
intestinal host responses. Furthermore, depletion of the 
mucin layer leads to an IBD-like phenotype and endo-
plasmic reticu lum stress, potentially driving IL-23 pro-
duc tion [21]. IL-23 excess alone is suffi  cient to induce 
spondyloarthritis in mice [22], and genetic evidence, in 
particular, indicates that the cytokine plays a key role in 
the development of spondyloarthritis in humans.
Permeability and disease
Th e dynamic crosstalk between IECs, microbes, and the 
local immune cells is fundamental to intestinal homeo-
stasis but is also suggested to play a part in disease 
pathogenesis [23]. In IBD and celiac disease, tight junc-
tions are dysregulated, causing increased permeability 
between IECs, resulting in a ‘leaky gut’ [24,25]. Studies 
looking at fi rst-degree relatives of patients with AS 
showed that they too have increased gut permeability, so 
it is likely that there is an underlying genetic process 
operating in the gut [26,27].
The immune barrier
Th e complexity of the intestinal immune system is the 
subject of many reviews, but here we will focus on some 
intestinal immune populations that are believed to be 
important in rheumatic disorders.
Innate immunity
Dendritic cells (DCs) densely populate the intestinal 
lamina propria and form a widespread microbe-sensing 
network. DCs recognize a broad repertoire of bacteria, 
sensing with receptors such as Toll-like receptors (TLRs) 
and monitoring the bacteria on the mucosal surface [28]. 
Intestinal DCs orchestrate production of intestine-
specifi c IgA to limit bacterial contact with the intestinal 
epithelial cell surface [29]. Activated DCs can secrete a 
number of cytokines and chemokines, including IL-23 
and IL-6, that are involved in infl am mation and migration 
of DCs [30].
Macrophages patrol the gastrointestinal systems in 
high numbers. Th ey frequently come in contact with 
‘stray’ bacteria, including commensals that have breached 
the epithelial cell barrier. Macrophages phagocytose and 
rapidly kill such bacteria by using mechanisms that 
include the production of antimicrobial proteins and 
reactive oxygen species [31]. Intestinal macrophages have 
several unique characteristics, including the expression 
of the anti-infl ammatory cytokine IL-10, both constitu-
tively and after bacterial stimulation [32,33]. Th is makes 
intestinal macrophages non-infl ammatory cells that still 
have the capacity to phagocytose. Th e importance of this 
pathway is highlighted by the fact that loss-of-function 
mutations in IL10R lead to early-onset IBD [34]. How-
ever, not all intestinal macrophages are non-infl amma-
tory. In patients with Crohn’s disease, a population of 
intestinal macrophages secrete infl ammatory cytokines 
such as IL-23, tumor necrosis factor-alpha (TNF-α), and 
IL-6. Th ese macrophages contribute to an infl ammatory 
microenvironment in patients with Crohn’s disease [35]. 
Intestinal macrophages also play a role in the restoration 
of the physical integrity of the epithelial cell barrier 
following injury or bacterial insult [24]. Re-establishing 
this barrier after injury is imperative to avoid bacterial 
penetration and sepsis in such a microbe-laden environ-
ment [36].
Adaptive immunity
IL-23-responsive cells
IL-23 is a key cytokine in the development of IL-17- and 
IL-22-secreting cells. IL-23 signals through a receptor 
consisting of the specifi c IL-23R subunit and IL-12Rβ1, 
also shared with IL-12R [37]. Loss-of-function polymor-
phisms in IL23R are associated with protection from AS 
[7], psoriasis [38], and IBD [39], and many other genes in 
the IL-23 pathway are associated with these diseases. 
Under physiological conditions, IL-23-, IL-17-, and IL-
22-producing cells are enriched in gut mucosa, and IL-17 
and IL-22 are known to be important regulators of 
intestinal ‘health’. IL-17 plays important roles in intestinal 
homoeostasis in several ways, including maintenance of 
epithelial barrier tight junctions [40] and induction of 
anti-microbial proteins such as β-defensins, S100 
proteins, and REG proteins. IL-22 induces secretion of 
anti-microbial peptides [41]. In the gut, innate-like 
immune cells act as sentinels, responding very rapidly to 
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alterations to the microbial composition of the gut with 
rapid secretion of IL-17. Key among these sentinels are 
γδ T cells, natural killer T (NKT) cells, mucosa-
associated invariant T (MAIT) cells, and lymphoid tissue 
inducer (LTi)-like cells (Figure 2).
γδ T cells
γδ T cells are found in large numbers at epithelial surfaces 
such as the gut and skin, where they can account for up 
to 50% of T cells. γδ T cells not only bear an antigen-
specifi c T-cell receptor (TCR) but also have many pro-
per ties of cells of the innate immune system, including 
expression of the major innate immunity receptors and 
TLRs [42] and dectin-1 [43], which recognizes microbial 
β-glucans. Expression of these receptors supports a role 
for γδ T cells in early responses to microbes. Of further 
relevance, we and others have recently confi rmed that 
CARD9, part of the dectin-1 response pathway, is a 
susceptibility gene for AS and IBD [44]. γδ T cells are 
potent producers of infl ammatory cytokines such as 
inter feron-gamma (IFN-γ), TNF-α, and IL-17 [45,46]. 
Th ey are pathogenic in the collagen-induced arthritis 
model [47] and mouse models of colitis [48], and IL-17-
secreting γδ T cells are expanded in patients with AS 
[49]. Intraepithelial γδ T cells also play an important role 
in modulating intestinal epithelial growth through 
secretion of fi broblast growth factor [50]. Alterations to 
γδ T-cell numbers or functions, therefore, may have 
profound eff ects on intestinal health.
Natural killer T cells
NKT cells are characterized by expression of an invariant 
TCR, Vα24Jα18 in humans and the orthologous 
Vα14Jα18 in mice. NKT cells recognize glycolipid struc-
tures presented to them by the non-classic antigen-
presenting molecule CD1d. Like γδ T cells, NKT cells are 
rapid responders to antigenic stimuli and are capable of 
producing a range of immunoregulatory cytokines 
[51-54]. Within the gut, NKT cells are protective in T 
helper 1 (TH1)-mediated models of IBD but are patho-
genic in TH2 models [55,56]. Recently, it has been shown 
that microbial stimulation of NKT cells in the gut of mice 
Figure 1. The physical barrier. Separating the intestinal lumen and its inhabiting commensal bacteria from the underlying lamina propria is a 
single layer of intestinal epithelial cells (IECs). These IECs are stitched together, creating a tight junction and regulating the paracellular fl ux. IECs 
also secrete soluble factors that are crucial to intestinal homeostasis, such as mucins and anti-microbial peptides (AMPs), including lysozymes, IgA, 
defensins, and C-type lectins such as RegIIIγ. Release of these molecules into luminal crypts is thought to prevent microbial invasion into the crypt 
microenvironment as well as limit bacteria-epithelial cell contact. Toll-like receptors (TLRs) are also expressed on IECs to sense a breach of barrier or 
bacterial invasion. Underneath the IECs, the lamina propria contains T cells, bacteria-sampling dendritic cells (DCs), and macrophages.
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aff ects NKT cell phenotypic and functional maturation 
[57,58]. Given that NKT cells have protective roles in 
models of arthritis [59] and SpA [60], their functional 
maturation in the gut provides evidence for a role for 
mucosal T-cell priming in infl ammatory joint disease.
Mucosa-associated invariant T cells
MAIT cells are a population of innate-like T cells that are 
abundant in human gut, liver, and blood and secrete a 
range of infl ammatory cytokines such as IL-17 and IFN-γ 
in response to antigenic stimulation [61-63]. Like NKT 
cells, MAIT cells bear an invariant TCR (Vα7.2 in 
humans) that recognizes antigen presented by the non-
classic MHC-like molecule, MR1 [64]. In blood, MAIT 
cells display a memory phenotype [63] and express the 
transcription factor ZBTB16 [65], allowing them to 
rapidly secrete cytokine in response to antigenic stimuli. 
Furthermore, they express high levels of IL-23R [66]. 
MAIT cells react to a wide range of microbial stimuli, 
including Gram-positive and Gram-negative bacteria as 
well as yeasts [61,62]. Although the precise role of MAIT 
cells in maintenance of the mucosal barrier remains 
unclear, the rapid postnatal expansion of MAIT cells and 
their acquisition of phenotypic markers of memory likely 
represent an interaction with developing commensal 
microfl ora [67].
Lymphoid tissue inducer-like cells and innate lymphoid cells
LTi-like cells are found in spleen, lymph node, and gut 
lamina propria. LTi-like cells constitutively express hall-
marks of IL-17-secreting cells, including IL-23R, RORγt, 
AHR, and CCR6 [68]. Stimulation of LTi-like cells with 
IL-23 induces IL-17 secretion [68], whereas PMA and 
ionomycin stimulation invokes secretion of IL-22 [69]. 
LTi cells appear to be related to an increasingly interest-
ing and heterogeneous population of innate lymphoid 
Figure 2. The immune barrier. Dendritic cells (DCs) and macrophages patrol the gastrointestinal tract in high numbers. They densely populate 
the intestinal lamina propria and form a widespread microbe-sensing network. Activated DCs can secrete a number of cytokines and chemokines, 
including interleukin-23 (IL-23), IL-6, and IL-1, activating IL-23-responsive cells. IL-23-, IL-17-, and IL-22-producing cells are enriched in gut mucosa, 
and IL-17 and IL-22 are known to be important regulators of intestinal ‘health’. IL-17 plays important roles in intestinal homoeostasis in several ways, 
including maintenance of epithelial barrier tight junctions. LTi, lymphoid tissue inducer; MAIT, mucosa-associated invariant T; NKT, natural killer T; 
T reg, regulatory T; TNF, tumor necrosis factor.
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cells (ILCs). ILCs have been linked to gut infl ammation 
through colitis models in which IL-23-responsive ILCs 
secrete IL-17 and IFN-γ and promote intestinal infl am-
mation [70]. NKp46+ ILCs are involved in host defense 
against Citrobacter rodentium infection through secre-
tion of IL-22 [71].
The human microbiome revolution
Together, the multi-factorial components of the immune 
system shape the microbial population that inhabits the 
gut and (to an extent) vice versa, with each side pushing 
to establish a stable state. Understanding the yin and 
yang of this relationship is at the heart of current micro-
biome research.
Microbiome refers to the totality of microbes, their 
genetic elements, and environmental interaction in a 
defi ned environment [72]. Projects such as the Human 
Microbiome Project, run by the National Institutes of 
Health, and the Metagenomics of the Human Intestinal 
Tract (MetaHit) consortium aim to determine what 
constitutes a ‘normal’ or healthy microbiome. Research in 
this fi eld has recently been greatly accelerated by the 
development of high throughput sequencing methods for 
microbial profi ling, which can profi le microbial popu la-
tions whether or not the microbes present can be cultured.
16S rRNA sequencing
16S rRNA is a section of prokaryotic DNA found in all 
bacteria and archaea. 16S rRNA sequences are used to 
diff erentiate between organisms across all major phyla of 
bacteria and to classify strains down to the species level 
[73]. 16S rRNA sequencing has dramatically changed our 
understanding of phylogeny and microbial diversity 
because it provides an unbiased assessment of the 
microbiome and is not restricted by the ability to culture 
the bacteria present.
Further improvements in sequencing technologies have 
reduced the need for targeted studies such as 16S sequen-
cing and enabled high-throughput shotgun sequencing. 
Th is latter type of sequen cing randomly samples all genes 
present in a habitat rather than just 16S rRNA. Shotgun 
sequencing provides more information about the micro-
biome than just the 16S characterization, which is of 
particular benefi t in determining the functional capacity of 
the microbial community rather than just its phylo geny. 
However, shotgun sequencing is more complex to analyze, 
owing in part to the challenge of distinguishing between 
host and bacterial genomic material, and requires far more 
sequencing to be performed. Th erefore, most studies to 
date have relied on 16S rRNA sequencing approaches.
Advances in tools for metagenomic studies
Several sequencing technologies have been developed for 
human genetic studies and have since been adapted to 
metagenomics. Th e Roche 454 sequencing platform 
(Roche, Basel, Switzerland) uses large-scale parallel 
pyrosequencing to produce reads of between 450 and 
1000 base pairs (bp) in length. Read lengths produced by 
the 454 platform are well suited to 16S rRNA amplicon 
metagenomics studies as well as shotgun sequencing as 
they are easily aligned to reference bacterial genetic data 
sets. Sequencing plat forms from Illumina (San Diego, 
CA, USA), the HiSeq2000 and MiSeq, produce shorter 
reads than the Roche 454. Th e HiSeq was designed 
primarily for human genomic sequencing, and current 
chemistry produces 100-bp paired-end reads. Illumina 
sequencing is best suited for shotgun sequencing or 
indexed amplicon sequencing of multiple samples.
Th is is a rapidly developing fi eld. Advances in chemistry 
are predicted to increase both read lengths and output 
for both of these platforms over the next 12 to 24 months, 
particularly for the Illumina platforms that are less 
mature than the Roche 454. New platforms coming to the 
market are likely to have a major impact on meta-
genomics study design. For example, the Pacifi c Bio-
sciences sequencing technology (Pacifi c Biosciences, 
Menlo Park, CA, USA) provides reads of approximately 
3,000 bases, which will make it particularly suited to this 
fi eld, despite its lower overall output (approximately 
100  Mb of sequence per run). Life Technologies Ion 
Torrent technology (Life Technologies, Grand Island, NY, 
USA) is reported to produce up to 400 base reads and up 
to 1  Gb of sequence per run. Th e relative positions of 
these competing technologies in metagenomics have yet 
to be established.
The normal human gut microbiome
To date, only a handful of studies have examined in any 
depth the function as well as the composition and 
diversity of the human gut microbiome. Two large studies 
interrogating and cataloguing microbiomes from various 
regions of the body in health and disease have been 
undertaken by the National Institutes of Health Human 
Microbiome Project in the US and the European MetaHit 
project [74-76]. Th e European MetaHit consortium 
combined published data sets from around the world and 
added 22 newly sequenced fecal metagenomes from four 
diff erent European countries. Th ey identifi ed three robust 
clusters, termed ‘enterotypes’, that were not nation- or 
continent-specifi c. Th ese enterotypes characterized the 
microbial phylogenetic variation as well as the function 
variation of the clusters at gene and functional class levels 
[74]. Each enterotype had a dominant bacterial genus: 
enterotype 1 was dominated by the genus Bacteriodes, 
enterotype 2 by Prevotella, and enterotype 3 by Rumino-
coccus. Th e three enterotypes were also shown to be 
functionally diff erent. For example, enterotype 2, which 
is Prevotella-dominant, also contains Desfulfovibrio, 
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which may act in synergy with Prevotella to degrade 
mucin glycoproteins present in the mucosal layer of the 
gut. It may be that diff erent enterotypes may be asso-
ciated with diseases such as obesity and IBD rather than 
necessarily specifi c bacterial species, given their diff ering 
functional capacities. Further studies will be required to 
determine whether enterotypes are consis tently found in 
expanded data sets and in studies of intestinal biopsies as 
well as the fecal samples used in the MetaHit study.
The microbiome in immune-mediated arthritis
Th e major fi ndings of microbial profi ling studies in major 
immune-mediated diseases associated with arthritis are 
summarised in Table  1. To date, no study investigating 
the gut microbiome by using sequencing-based methods 
in AS has been reported. Many studies largely using 
antibody tests have suggested an increased carriage of 
Klebsiella species in patients with AS, but this has not 
been universally supported [77]. One study using 
denaturing gradient gel electrophoresis to profi le the 
microbiome by using fecal samples found no diff erences 
between AS cases and healthy controls [78].
Rheumatoid arthritis (RA) is the only infl ammatory 
arthritis for which modern metagenomic studies have 
been reported. Community profi ling studies of gut fl ora 
of patients with RA reveal diff erences in the composition 
of gut microbiota of patients with RA compared with 
those of healthy controls, and a lower abundance of 
Bifi dobacterium and Bacteroides bacteria was observed 
in RA cases [79,80]. However, these studies used fecal 
samples and not intestinal biopsies, possibly infl uencing 
the populations observed [81]. Also, microbial profi ling 
data suggest that gingival infection may be important, 
particularly in anti-citrullinated peptide antibody-posi-
tive RA, although the studies suggesting this have 
generally used antibody tests rather than sequencing-
based approaches (reviewed in [82]).
Several lines of evidence indicate that the gut micro-
biome plays an important role in IBD, including the 
association of genes involved in mucosal immunity with 
IBD (such as CARD15, CARD9, IL-23R, and ATG16L1), 
the therapeutic eff ect of antibiotics on the condition, and 
the benefi cial eff ect of fecal stream diversion in Crohn’s 
disease. Previous studies of human IBD have been under-
taken by using standard culture techniques (for example, 
[83]) or molecular analysis (for example, [84,85]). Th ese 
studies noted alterations in intestinal microbiota when 
compared with non-IBD patients, a fi nding recently 
confi rmed by using 16S rRNA sequencing of intestinal 
biopsies [86]. Th is sequencing study, however, did not 
identify an IBD-specifi c microbial profi le, perhaps because 
of insuffi  cient resolution of the sequencing performed or 
small sample size (12 patients and 5 controls). Much larger 
studies will be required to dissect the relationship 
between the host genetic factors determining risk of IBD 
and the gut microbiome.
Th e microbiome is thought to play a signifi cant role in 
psoriasis, another AS-related condition. It has long been 
suggested that streptococcal infection, especially throat 
infections, may trigger psoriasis in a genetically suscep-
tible individual [87]. Recent studies using 16S rRNA 
sequencing have found signifi cant diff erences between 
the cutaneous microbiota of psoriasis cases and controls 
and in involved and control skin in psoriasis cases, and 
less staphylococci and propionibacteria have been ob-
served in cases and in aff ected skin [88]. Again, further 
studies will be required to determine whether there is a 
particular microbial profi le or specifi c bacterial species 
involved in psoriasis.
Th ese studies are thus consistent with the hypothesis 
that the microbiome contributes to the etiopathogenesis 
of immune-mediated arthritis or seronegative diseases 
like IBD and psoriasis. However, at this point, there is no 
defi nitive evidence of specifi c bacterial infections or 
changes in microbial profi le that play a causative role in 
these conditions (with the exception of reactive arthritis).
Chicken and the egg
Whether the changes noted in these early metagenomic 
studies of immune-mediated disease are a consequence 
of disease or are involved in its development or persis-
tence is unclear. Th is distinction may prove impossible to 
dissect in human studies, but considerable evidence in 
studies in mice supports a role for the microbiome in 
driving immune-mediated diseases.
In the B27 rat model of AS, rats housed under GF 
conditions did not develop disease [89], demonstrating 
that microbes in this model are important for disease 
penetrance. In contrast, in the New Zealand black model 
of systemic lupus erythematosus, mice maintained under 
GF conditions produced higher levels of antinuclear 
antibodies and developed worse disease [90], 
demonstrating a protective role for commensal microbes.
Given the IL-17/IL-22 cytokines, which are of relevance 
to AS, IBD, and psoriasis in particular, strong evidence 
from murine studies indicates that interaction between 
the gut microbiome and the host determines the overall 
level of activation of the immune cells producing these 
cytokines. Segmented fi lamentous bacteria (SFB) are 
com mensal bacteria that induce IL-17 secretion. Mice 
lacking SFB have low levels of intestinal IL-17 and are 
susceptible to infection with pathogenic Citrobacter spp. 
Restoration of SFB in these mice increased the number of 
gut-resident IL-17-producing cells and enhanced resis-
tance to infection [12]. Salzman and colleagues [91] 
illustrated that α-defensins modulate mucosal T-cell 
response by regulating the composition, but not the total 
numbers, of bacteria in the intestinal microbiome. 
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Examin ing the intestinal microbiota of mice expressing 
the human α-defensin gene, they demonstrated signifi -
cant α-defensin-dependent alterations in commensal 
composition, leading to a loss of SFB and fewer IL-17-
producing lamina propria T cells [91]. Furthermore, 
using recolonization studies, investigators recently demon-
strated that, in neonatal mice, commensal microbes 
infl uence invariant NKT (iNKT) cell intestinal infi ltration 
and activation, establishing mucosal iNKT cell tolerance 
to later environmental exposures [92].
Th e mechanism by which the microbiome infl uences 
IL-17-producing cell activation is still being determined. 
Ivanov and colleagues [12] demonstrated that serum 
amyloid A, produced in the terminal ileum, can induce 
TH17 diff erentiation of CD4+ T lymphocytes. It has also 
been shown that development of TH17 lymphocytes in 
the intestine is stimulated by microbiota-induced IL-1β 
(but not IL-6) production [93]. Colonization with 
Clostridial species has been shown to stimulate intestinal 
transforming growth factor-beta (TGF-β) production, in 
turn increasing IL-10+ CTLA4high Treg (regulatory T) 
activation [94]. Clostridial coloniza tion of neonatal mice 
reduced severity of induced colitis by using dextran 
sulphate sodium or oxazolone and reduced serum IgE 
levels in adulthood. So it is likely that alterations to the 
gut microfl ora or invasion of the gut by pathogenic 
bacteria infl uences the balance of IL-17- and IL-22-
producing cells and other immune cells, infl uen cing 
susceptibility to local and systemic immune-mediated 
disease.
Th e above studies highlight that changes in the micro-
biome can lead to infl ammation which may have far-
reaching eff ects and demonstrate experimental approaches 
by which fi ndings of metagenomic studies in mice and 
humans can be explored to successfully dissect the role of 
the microbiome in human immune-mediated diseases.
Conclusions
Th e human gut microbiome is a dynamic and complex 
ecosystem that is only now beginning to be understood. 
Table 1. Alterations in gut microbiota associated with immune-mediated diseases 
Associated microbes Microbiota changes References
IBD – Crohn’s disease
Gut microbiome
Bacteroides ovatus 
Bacteroides vulgatus 
Bacteroides uniformis 
Reduction in microbial diversity when compared with controls [95]
IBD
Gut microbiome
Bacteroidetes 
Lachnospiraceae 
Actinobacteria 
Proteobacteria 
Clostridium 
Firmicutes/Bacteroidetes ratio 
Bifi dobacteria 
Associated with overall community shift and dysbiosis [96]
Celiac disease
Gut microbiome
Bacteroides vulgatus 
Escherichia coli 
Clostridium coccoides 
Overall higher diversity of microbes in patients with celiac disease compared with controls [97]
Psoriasis
Skin microbiome
Firmicutes 
Bacteroidetes 
Actinobacteria 
Proteobacteria 
Overrepresentation of Firmicutes and an underrepresentation of Actinobacteria and 
Proteobacteria when compared with controls 
[98,99]
Rheumatoid arthritis
Oral microbiome
Porphyromonas gingivalis 
Dysbiosis and increased diversity [100,101]
IBD, infl ammatory bowel disease.
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It is increasingly clear that the interaction between host 
and microbiome profoundly aff ects health. It is still 
unclear how interactions between host genes, microbes, 
and environmental factors can predispose patients to the 
development autoimmune diseases such as AS. We are 
only beginning to grasp the infl uence the microbiome has 
on health. Improved knowledge of the composition and 
function of the gut microbiome in patients with AS and 
how the microbiome shapes the immune response and 
infl uences infl ammation, both local and systemic, will 
likely provide important insights into early events in the 
pathogenesis of AS.
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